EVOTEC (UK) LIMITED

Their core work

Evotec (UK) Limited is the UK arm of the Evotec drug discovery group, based in Abingdon near Oxford, specializing in computational approaches to biomedicine and drug design. Within H2020, they contributed computational modelling and simulation expertise to large-scale biomedicine centres of excellence, and provided drug discovery capabilities for infectious disease research targeting fungal pathogens. Their work sits at the intersection of high-performance computing, molecular simulation, and translational medicine.

What they specialise in

How they've shifted over time

Their early H2020 work (2016-2018) centred on computational biomedicine — multiscale modelling and HPC simulation for personalised medicine through the CompBioMed centre of excellence. From 2019 onward, they broadened into infectious disease biology via FunHoMic (fungal infections, microbiota, immunology) while deepening their computational work with exascale computing in CompBioMed2. The trajectory shows a company expanding from pure computational services toward domain-specific disease applications where those computational tools can be directly applied.

Moving toward applying exascale computational power to specific therapeutic areas like infectious disease, suggesting future interest in computationally-driven drug discovery collaborations.

How they like to work

Evotec (UK) never coordinated an H2020 project, consistently joining as a participant or third party — typical of an industrial partner contributing specialist capabilities to academically-led consortia. With 35 unique partners across 9 countries from just 3 projects, they operate in large, diverse consortia (the CompBioMed projects alone are major multi-partner efforts). This profile suggests a reliable industrial contributor that brings commercial drug discovery infrastructure to research-driven projects.

Despite only 3 projects, they have built connections with 35 partners across 9 countries, driven by the large CompBioMed consortia. Their network is predominantly European with strong ties to computational biomedicine and infectious disease research communities.

What sets them apart

Evotec (UK) bridges the gap between academic computational research and industrial drug discovery — few private companies bring both HPC simulation expertise and compound screening capabilities to EU consortia. Based in Oxfordshire's life sciences cluster, they offer a commercial translation pathway for research outputs. For consortium builders, they represent an industry partner that can take computational and biological insights closer to actual drug candidates.

Highlights from their portfolio

• CompBioMed2
  Centre of Excellence in Computational Biomedicine scaled to exascale computing (2019-2024), representing one of the flagship HPC-for-health initiatives in H2020.
• FunHoMic
  Marie Curie training network on fungal infections — unusual for a pharma company to join a training programme, signalling commitment to building the next generation of infectious disease researchers.